# Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

> **NCT05043714** · PHASE1 · COMPLETED · sponsor: **Akamis Bio** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Cancer
- Epithelial Tumor

## Interventions

- **BIOLOGICAL:** NG-641 in combination with Nivolumab

## Key facts

- **NCT ID:** NCT05043714
- **Lead sponsor:** Akamis Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-11-13
- **Final completion:** 2024-10-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043714, "Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05043714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*